Pathways towards an effective immunotherapy for Parkinson's disease - Wikidata - awgldk - TriplyDB

Pathways towards an effective immunotherapy for Parkinson's disease

Pathways towards an effective immunotherapy for Parkinson's disease

http://www.wikidata.org/entity/Q37957125

about

Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease.First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model.Immunity and inflammation in neurodegenerative diseases.Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

P2860

Q27015811-F27063F6-0AB0-4658-9C91-4F630B844F36 Q35058359-884502BE-EC5F-4898-8C5E-024A73A6E023 Q36326816-57825CF7-49DE-45FD-A3A3-147AB3BEEAE4 Q36484413-048877F8-736A-485B-8460-D2393E278991 Q37274056-CEDA27AC-5329-492F-A659-D9E76301A0EA Q37664213-13589EEF-1BAE-498E-A530-2EC4BB0D5B20 Q38823785-37AE7E6F-EAC3-4EB4-963A-9795774641A8 Q42048890-AB76F51F-EEEB-4A32-A088-EE59066592D6 Q43104143-71187223-EC60-476C-99FC-A75DAD7A3B44 Q45201060-7B8F5F26-82D4-41C4-BB64-12EC3DB532D6

P2860

Pathways towards an effective immunotherapy for Parkinson's disease

http://www.wikidata.org/entity/Q37957125

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pathways towards an effective immunotherapy for Parkinson's disease

@en

Pathways towards an effective immunotherapy for Parkinson's disease.

@nl

type

label

Pathways towards an effective immunotherapy for Parkinson's disease

@en

Pathways towards an effective immunotherapy for Parkinson's disease.

@nl

prefLabel

Pathways towards an effective immunotherapy for Parkinson's disease

@en

Pathways towards an effective immunotherapy for Parkinson's disease.

@nl

P1433

Q37957125-2A18602F-E5BF-45A9-ADF4-0E41AB65CFE5

P1476

Q37957125-AB023A6E-51BC-4AE6-A130-21ED4823AB59

P2093

Q37957125-2A4B1EDD-5F39-4877-852A-C8DC56D4F167

Q37957125-7496E633-DBF8-40C5-B5D1-ED953129B5E1

Q37957125-74DDDEF7-8E21-4CD8-8066-7F1ABC1566ED

P2860

Q37957125-007672A1-6C58-4782-A9A3-0114CDE072A3

Q37957125-038A120A-8795-4E93-A2C5-DB5B5C0CFF16

Q37957125-06B6FBA3-DAE1-4CCB-A1F6-3017A6C42BE8

Q37957125-08FE024F-02A0-4A87-9F7E-BBD44D7FF407

Q37957125-0A097DBB-B9DA-4E4E-8B07-B37F5B998026

Q37957125-0C4389B3-ACA8-4565-841A-A7026C2EF105

Q37957125-0DA65FB2-6E2A-4605-8C5B-F79C503188BE

Q37957125-0DE605D8-262A-4141-93E7-36BD9BEBBD04

Q37957125-0E5A0688-88AA-486F-96E7-29159E89C7CF

Q37957125-0EEB0A61-822A-4067-A5CB-6BA9D2D53D54

P304

Q37957125-05BB6CCB-39A3-4E1D-B5E5-6D7F10C37460

P31

Q37957125-3F24298F-1CC7-431A-ADBC-D80D7CD80B3B

P356

Q37957125-7AB06547-A87B-4AB8-B88A-FA22133A3F4A

P433

Q37957125-72007940-2687-4CAC-920E-58AF3A546222

P478

Q37957125-9A8D92BA-10A3-419D-B8E9-951E8536C757

P577

Q37957125-2B09C44E-AE79-41C4-B7C9-F0DDD2111378

P5875

Q37957125-BD26A6F3-EC0D-4597-9C04-A6BB29600B6C

P698

Q37957125-B182F989-A0C6-4F51-8569-C9C766200F18

P921

Q37957125-6DE17983-F28E-4D4E-89E4-322AEC2610E3

Q37957125-E07405E2-0DC0-4088-8515-DDC8B5D28102

P932

Q37957125-0F7347DA-8954-43B2-955A-B464378C4E42

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Pathways towards an effective immunotherapy for Parkinson's disease

@en

P2093

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

Jessica A L Hutter-Saunders

http://www.w3.org/2001/XMLSchema#string

Rodney Lee Mosley

http://www.w3.org/2001/XMLSchema#string

P2860

Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs

Functional recovery in parkinsonian monkeys treated with GDNF

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system.

Role of microglia in central nervous system infections

Use of ibuprofen and risk of Parkinson disease

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms

Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation.

Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?

P304

1703-1715

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.11.163

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51808940

http://www.w3.org/2001/XMLSchema#string

P698

22091596

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3263336

http://www.w3.org/2001/XMLSchema#string